Publications by authors named "Hans-Georg Rhein"
Background: Between 80 and 90 million travellers visit malaria endemic areas annually and many require malaria chemoprophylaxis. The characterization of the risk and nature of eye disorders occurring during the use of malaria chemoprophylaxis is relevant for travel medicine advisors.
Methods: We did a database analysis on eye disorder adverse events reported for mefloquine (as Lariam®) using the F.
Use of anti-malarial drugs and the risk of developing eye disorders.
Travel Med Infect Dis
September 2014
Background: Ocular toxicity was described in the late 1950s for some anti-malarial drugs, but only limited information is available on the comparison of ocular toxicity of different anti-malarials.
Methods: We conducted a follow-up study with a nested case-control analysis using the General Practice Research Database to compare the risk of developing a first-time diagnosis of an eye disorder during exposure of mefloquine, chloroquine and/or proguanil or atovaquone/proguanil use to non-users. We calculated incidence rates with 95% confidence intervals (CI) and odds ratios using multivariate conditional logistic regression analyses.
Background: Case reports and epidemiological studies have associated the use of mefloquine with neuropsychiatric adverse events.
Methods: We used the General Practice Research Database to conduct a follow-up study with a nested case-control analysis. We assessed the risk of developing first-time anxiety, stress-related disorders/psychosis, depression, epilepsy or peripheral neuropathies in patients using mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil for malaria chemoprophylaxis, as compared to unexposed travelers.
Background: Pregnant women who travel to malarious areas and their clinicians need data on the safety of malaria chemoprophylaxis.
Methods: The effect of exposure to mefloquine on pregnancy and offspring outcomes was evaluated using the F. Hoffmann-La Roche global drug safety database for the time frame 31 January 1986 through 26 October 2010.
Background: Use of anti-malarial medication in children is hampered by a paucity of dosage, pharmacokinetic and tolerability data.
Methods: Data on the use of mefloquine in children, particularly in young children weighing less than 20 kg, were reviewed using PubMed literature and reports on file.
Results: Chemoprophylaxis data: Two studies with a total of 170 children were found.
Background: Malaria chemoprophylaxis prevents the occurrence of the symptoms of malaria. Travellers to high-risk Plasmodium falciparum endemic areas need an effective chemoprophylaxis.
Methods: A literature search to update the status of mefloquine as a malaria chemoprophylaxis.